• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.

作者信息

Muguruma Yukari, Yahata Takashi, Warita Takayuki, Hozumi Katsuto, Nakamura Yoshihiko, Suzuki Rikio, Ito Mamoru, Ando Kiyoshi

机构信息

Center for Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan.

Department of Hematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya Isehara, Kanagawa, 259-1193, Isehara, Japan.

出版信息

Blood Cancer J. 2017 Dec 15;7(12):650. doi: 10.1038/s41408-017-0001-3.

DOI:10.1038/s41408-017-0001-3
PMID:29242532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5802593/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e47d/5802593/80a1a10fce14/41408_2017_1_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e47d/5802593/6fe70db3f84a/41408_2017_1_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e47d/5802593/80a1a10fce14/41408_2017_1_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e47d/5802593/6fe70db3f84a/41408_2017_1_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e47d/5802593/80a1a10fce14/41408_2017_1_Fig2_HTML.jpg

相似文献

1
Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.锯齿状蛋白1诱导的Notch激活促进骨髓瘤细胞对硼替佐米耐药性的获得。
Blood Cancer J. 2017 Dec 15;7(12):650. doi: 10.1038/s41408-017-0001-3.
2
MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.微小RNA-324-5p通过靶向刺猬信号通路调控多发性骨髓瘤细胞的干性、发病机制及对硼替佐米的敏感性。
Int J Cancer. 2018 Jan 1;142(1):109-120. doi: 10.1002/ijc.31041. Epub 2017 Sep 30.
3
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.多发性骨髓瘤衍生的锯齿状配体增加骨髓微环境中的自分泌和旁分泌白细胞介素-6表达。
Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.
4
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.唾液型淀粉酶的过表达降低了多发性骨髓瘤细胞对硼替佐米的敏感性。
Int J Hematol. 2015 Nov;102(5):569-78. doi: 10.1007/s12185-015-1859-0. Epub 2015 Sep 4.
5
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.Dll1/Notch 激活通过上调多发性骨髓瘤中的 CYP1A1 导致硼替佐米耐药。
Biochem Biophys Res Commun. 2012 Nov 30;428(4):518-24. doi: 10.1016/j.bbrc.2012.10.071. Epub 2012 Oct 27.
6
Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.Jagged1 通过调节乳腺癌患者肿瘤相关巨噬细胞的分化促进芳香酶抑制剂耐药性。
Breast Cancer Res Treat. 2017 Nov;166(1):95-107. doi: 10.1007/s10549-017-4394-2. Epub 2017 Jul 20.
7
BAFF is involved in macrophage-induced bortezomib resistance in myeloma.BAFF 参与骨髓瘤中巨噬细胞诱导的硼替佐米耐药。
Cell Death Dis. 2017 Nov 2;8(11):e3161. doi: 10.1038/cddis.2017.533.
8
MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.MTDH是多发性骨髓瘤中的一种癌基因，其受到硼替佐米治疗的抑制。
Oncotarget. 2016 Jan 26;7(4):4559-69. doi: 10.18632/oncotarget.6610.
9
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.蛋白酶体抑制剂 BSc2118 对人多发性骨髓瘤的抗肿瘤活性。
Cancer Lett. 2015 Oct 1;366(2):173-81. doi: 10.1016/j.canlet.2015.06.011. Epub 2015 Jun 23.
10
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.CCR10/CCL27相互作用导致蛋白酶体抑制剂在多发性骨髓瘤中失效。
Oncotarget. 2016 Nov 29;7(48):78605-78618. doi: 10.18632/oncotarget.12522.

引用本文的文献

1
Nestin in multiple myeloma: emerging insights into a potential therapeutic target.巢蛋白在多发性骨髓瘤中的作用：对潜在治疗靶点的新见解
Front Oncol. 2025 Jul 29;15:1596928. doi: 10.3389/fonc.2025.1596928. eCollection 2025.
2
Azvudine Suppresses Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the Notch-HEY Signalling Pathway.阿兹夫定通过靶向Notch-HEY信号通路抑制肝细胞癌的上皮-间质转化
Int J Mol Sci. 2025 May 27;26(11):5127. doi: 10.3390/ijms26115127.
3
Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.

本文引用的文献

1
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.MARCKS 有助于基质癌相关成纤维细胞的激活，并促进卵巢癌转移。
Oncotarget. 2016 Jun 21;7(25):37649-37663. doi: 10.18632/oncotarget.8726.
2
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.靶向磷酸化 MARCKS 可克服耐药性并在多发性骨髓瘤的临床前模型中诱导抗肿瘤活性。
Leukemia. 2015 Mar;29(3):715-26. doi: 10.1038/leu.2014.255. Epub 2014 Sep 2.
3
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.
泛素蛋白酶体系统（UPS）：癌症表观遗传格局的关键决定因素。
Epigenomics. 2025 Jun;17(9):625-644. doi: 10.1080/17501911.2025.2501524. Epub 2025 May 8.
4
A comprehensive review of oncogenic Notch signaling in multiple myeloma.多发性骨髓瘤中致癌性Notch信号通路的综合综述。
PeerJ. 2024 Nov 28;12:e18485. doi: 10.7717/peerj.18485. eCollection 2024.
5
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。
Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.
6
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma.一种由NOTCH3-CXCL12驱动的骨髓瘤-肿瘤微环境信号轴促进多发性骨髓瘤的化疗耐药性。
Haematologica. 2024 Aug 1;109(8):2606-2618. doi: 10.3324/haematol.2023.284443.
7
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.表观遗传改变作为硼替佐米分子作用的重要方面
Cancers (Basel). 2023 Dec 23;16(1):84. doi: 10.3390/cancers16010084.
8
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma.JAG 配体在多发性骨髓瘤中的治疗靶点和预测性生物标志物潜力。
Int J Mol Sci. 2023 Sep 26;24(19):14558. doi: 10.3390/ijms241914558.
9
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.恶性肿瘤前期和活动期骨髓瘤患者的 B 细胞淋巴生成的异质性。
JCI Insight. 2023 Feb 8;8(3):e159924. doi: 10.1172/jci.insight.159924.
10
Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling.BRAF抑制剂耐药黑色素瘤细胞中MARCKS活性增加对其增强的转移行为至关重要，这与WNT5A和IL-6信号升高无关。
Cancers (Basel). 2022 Dec 10;14(24):6077. doi: 10.3390/cancers14246077.
多发性骨髓瘤中的耐药性：分子机制的最新发现与新概念
Oncotarget. 2013 Dec;4(12):2186-207. doi: 10.18632/oncotarget.1497.
4
Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Notch 靶向的骨髓瘤微环境重编程：单一途径通向多种结果。
Leukemia. 2013 Apr;27(5):1009-18. doi: 10.1038/leu.2013.6. Epub 2013 Jan 11.
5
Proteasome inhibitors in multiple myeloma: 10 years later.蛋白酶体抑制剂在多发性骨髓瘤中的应用：10 年进展。
Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29.
6
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.致癌和抑癌作用的 Notch 信号通路在癌症中的作用：它并不像你想的那样 Notch。
J Exp Med. 2011 Sep 26;208(10):1931-5. doi: 10.1084/jem.20111855.
7
Multiple myeloma.多发性骨髓瘤
N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442.
8
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.应用基于质谱的蛋白质组学技术来深入了解多发性骨髓瘤。
J Hematol Oncol. 2010 Apr 7;3:13. doi: 10.1186/1756-8722-3-13.
9
Dynamic adhesions and MARCKS in melanoma cells.黑色素瘤细胞中的动态黏附与MARCKS蛋白
J Cell Sci. 2009 Jul 1;122(Pt 13):2300-10. doi: 10.1242/jcs.047860. Epub 2009 Jun 9.
10
Bone marrow microenvironment and the identification of new targets for myeloma therapy.骨髓微环境与骨髓瘤治疗新靶点的鉴定
Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9.